Skip to main content

Multiple Sclerosis Discovery Forum

Inspiring Connections

Utility Navigation

Feedback
Newsletter
RSS
Twitter

User Top Menu

Welcome, guest
Log In
Join
Why Join?

Search form

Search

About Us
- Overview
- Who We Are
- Contact
- Fan Mail
- How to Cite
News & Future Directions
Papers
Forums
- Discussions
- Webinars
Professional Resources
Research Resources
Click Here to Support MSDF

You are here

Most Viewed

Tcelna® (imilecleucel-T)
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Federation of Clinical Immunology Societies 2012
New multiple sclerosis phenotypic classification.
Limit cycle oscillations in standing human posture.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
The scales and tales of myelination: using zebrafish and mouse to study myelinating glia.
PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis.
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
ARESTIN®
Glatiramer acetate ameliorates experimental autoimmune neuritis.
The interplay between the intestinal microbiota and the brain.
Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
4th Biannual NeuroUnit Biomarkers for Inflammation and Neurodegeneration Symposium on Biomarkers in Neurodegenerative Disease
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Regenerative cellular therapies for neurologic diseases.
EMD Serono
Alemtuzumab
Merck: Regulatory Update on Cladribine Tablets
Epigenome-wide differences in pathology-free regions of multiple sclerosis-affected brains.
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients

Pages

« first
‹ previous
…
107
108
109
110
111
112
113
114
115
…
next ›
last »

MSDF Footer

Copyright © 2014 MGH and ACP

Privacy
Terms of Use
How to Cite
FAQ/Help
Site Map
Support Us
Feedback
Image Credits

All site content, except where otherwise noted, is licensed under a Creative Commons BY license. Please let us know where and how you use MSDF material.

Content By

Software By